Researcher
Marc Peeters
- Research Expertise (University of Antwerp):My expertise is in the field of oncology or cancer research. It is mainly focused on clinical translational research. This domain is very broad and ranges from bio-research to clinical studies
- Keywords (University of Antwerp):ONCOLOGY, Medicine
- Disciplines (Ghent University):Endocrinology and metabolic diseases, Paediatrics and neonatology, Nursing
- Disciplines (University of Antwerp):Cancer therapy, Cancer biology, Cancer diagnosis, Cancer epidemiology, Cancer prevention
- Research techniques (University of Antwerp):Making protocols for studies. (Statistical) analysis of results
- Users of research expertise (University of Antwerp):Other researchers in the field. Students Pharma and Biotech companies
- See also: Marc Peeters (Ghent University)
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Responsible
From1 Oct 2009 → 31 Dec 2018 - Department of Internal medicine (Department)
Member
From1 Oct 2000 → 30 Sep 2018
Projects
21 - 30 of 67
- Acquired immunity and immunologic aspects of SARS-CoV-2 infection a population of patients and healthcare workers in Multidisciplinary Oncologic Centres. (MOCOR-Study).From1 Jun 2020 → 31 May 2021Funding: BOF - projects
- Validation of a new combination immunotherapy for cancer: treatment with a CD40 agonist and interleukin- 15From1 May 2020 → 30 Apr 2021Funding: IOF - technology validation in lab, Own budget, for example: patrimony, inscription fees, gifts
- Improving current cancer detection and treatment follow-up through the development of a next generation cancer assay.From1 Feb 2020 → 31 Jan 2023Funding: IOF - technology concept exploration
- Therapeutic dendritic cell vaccination to improve frontline treatment of adult patients with glioblastoma multiforme (GBM) and pediatric patients with GBM and diffuse intrinsic pontine glioma (DIPG).From1 Jan 2020 → TodayFunding: Nonprofit institution or equivalents
- Improving current cancer detection and treatment follow up through the development of next generation cancer assays.From1 Jan 2020 → 31 Dec 2023Funding: BOF - projects
- Integrated Personalized & Precision Oncology Network (IPPON).From1 Jan 2020 → TodayFunding: BOF - research organisations, Fund Recuperation Fiscal Exemption
- Identification of pan-cancer and tumor-specific methylation based biomarkers and development of bioinformatics infrastructure for a novel multiplex methylation assay.From1 Nov 2019 → 31 Oct 2023Funding: FWO fellowships
- Development of a multi-region methylation blood based test for pan-cancer detection.From1 Nov 2019 → 30 Oct 2020Funding: BOF - doctoral mandates
- Development of a novel immunometabolic combination strategy for glioblastoma.From1 Oct 2019 → TodayFunding: Nonprofit institution or equivalents
- Identification of genetic markers for everolimus-resistance in patients with pancreatic neuroendocrine tumors.From1 Oct 2019 → 30 Sep 2021Funding: FWO fellowships
Publications
1 - 10 of 385
- Bleeding and perforation complications after follow-up colonoscopies in faecal immunochemical test-based colorectal cancer screening(2024)
Authors: Thuy Ngan Tran, Joanna Bouchat, Marc Peeters, Bea Berghmans, Eric Van Cutsem, Guido Van Hal, Koen Van Herck, Sarah Hoeck
Pages: 26 - 48 - Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from t(2024)
Authors: C.S. Karapetis, H. Liu, M.J. Sorich, L.D. Pederson, E. Van Cutsem, T. Maughan, J.Y. Douillard, C.J. O'Callaghan, D. Jonker, C. Bokemeyer, et al.
- Hyperthermia in combination with emerging targeted and immunotherapies as a new approach in cancer treatment(2024)
Authors: Tine Logghe, Eke van Zwol, Benoit Immordino, Kris van den Cruys, Marc Peeters, Elisa Giovannetti, John-Paul Bogers
Pages: 1 - 35 - Auranofin repurposing for lung and pancreatic cancer(2024)
Authors: Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, et al.
Pages: 1 - 15 - Relationship between health-related determinants and adherence to breast and colorectal cancer screening(2024)
Authors: Allegra Ferrari, Thuy Ngan Tran, Sarah Hoeck, Marc Peeters, Mathijs Goossens, Guido Van Hal
Pages: 347 - 353 - Treatment of ambulatory patients with metastatic epidural spinal cord compression(2024)
Authors: Ruben Van den Brande, Dieter Thijs, Mark Bilsky, Marc Peeters
Pages: 175 - 184 - New developments in treating RAS-mutated metastatic colorectal cancer(2023)
Authors: Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters
Pages: 965 - 987 - Increasing adherence to prophylactic swallowing exercises during head and neck radiotherapy(2023)
Authors: Margot Baudelet, Frederic Duprez, Leen Van den Steen, Sandra Nuyts, Ann Goeleven, Caroline Vandenbruaene, Hanne Massonet, Alice Vergauwen, Heleen Bollen, Sarah Deschuymer, et al.
Pages: 886 - 895 - Implementation of PROs in daily oncology care before and during the SARS-CoV-2 pandemic(2023)
Authors: Marika Rasschaert, Marc Peeters, Peter Van Dam, Annelies J R Janssens
Number of pages: 120 - A Belgian population-based study reveals subgroups of right-sided colorectal cancer with a better prognosis compared to left-sided cancer(2023)
Authors: Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Pages: e331 - e340
Patents
1 - 6 of 6
- Combination immunotherapy of il-15 and cd40 agonist in cancer treatment (Inventor)
- Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment (Inventor)
- Methylation detection assay (Inventor)
- Methylation status of gasdermin E gene as cancer biomarker (Inventor)
- Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment (Inventor)
- Methylation status of gasdermin e gene as cancer biomarker (Inventor)